Lyell Immunopharma
LYELLYEL · Stock Price
Historical price data
Overview
Lyell Immunopharma is a clinical-stage biotech founded in 2018 with a mission to fully realize the curative potential of cell therapy for cancer. The company is advancing a pipeline of next-generation CAR-T therapies, featuring a pivotal-stage dual-targeting candidate for large B-cell lymphoma and a Phase 1 program for metastatic colorectal cancer. Its strategy is built on deep T-cell biology expertise, proprietary manufacturing, and vertical integration to improve outcomes in hematologic malignancies and pioneer breakthroughs in solid tumors.
Technology Platform
An integrated platform combining epigenetic reprogramming (Epi-R) to prevent T-cell exhaustion, novel dual-targeting CAR constructs, and a specialized manufacturing process (Gen-R) to generate T cells with a stem-like memory phenotype for enhanced potency and persistence.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| rondecabtagene autoleucel + axicabtagene ciloleucel + lisoca... | Large B-cell Lymphoma | Phase 3 | |
| IMPT-514 + IMPT-514 + IMPT-514 | Systemic Lupus Erythematosus | Phase 1/2 | |
| LYL314 + Fludarabine + Cyclophosphamide | Relapsed Non-Hodgkin Lymphoma | Phase 1/2 | |
| LYL797 | Triple Negative Breast Cancer | Phase 1 | |
| GCC19CART | Colorectal Cancer | Phase 1 |
Opportunities
Risk Factors
Competitive Landscape
In lymphoma, Lyell competes with approved CD19 CAR-Ts (Yescarta, Kymriah, Breyanzi) and bispecific antibodies, differentiating via dual CD19/CD20 targeting. In solid tumors, it faces a less crowded but scientifically challenging field against other investigational cell therapies and TCR-based approaches.
